CHORDIA THERAPEUTICS INC (190A.T)
JPY 250.0
(0.0%)
JPY 250.0
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | - | 2.5 Billion | - | 800 Million |
| Cost of Revenue | 4.09 Million | - | 3.14 Million | - |
| Gross Profit | -4.09 Million | 2.5 Billion | -3.14 Million | 800 Million |
| Operating Expenses | 1.79 Billion | 2.28 Billion | 1.84 Billion | 1.38 Billion |
| Selling, General and Administrative Expenses | 297.5 Million | 285.07 Million | 184.85 Million | 170.74 Million |
| Research and Development Expenses | 1.49 Billion | 1.99 Billion | 1.65 Billion | 1.21 Billion |
| Other Expenses | - | - | 55.49 Million | 162.86 Million |
| Cost and Expenses | 1.8 Billion | 2.28 Billion | 1.84 Billion | 1.38 Billion |
| Operating Income | -1.8 Billion | 212.05 Million | -1.84 Billion | -587.66 Million |
| Interest Expense | - | - | - | - |
| Income Tax Expense | 2.42 Million | 2.42 Million | 2.42 Million | 1.9 Million |
| Earnings before Tax | -1.82 Billion | 225.76 Million | -1.77 Billion | -525.2 Million |
| Net Income | -1.82 Billion | 223.34 Million | -1.77 Billion | -527.1 Million |
| Earnings Per Share Basic | -31.11 | 3.96 | -39.78 | -15.08 |
| Earnings Per Share Diluted | -31.11 | 3.96 | -39.78 | -15.08 |
| Weighted Average Shares Outstanding | 58.72 Million | 56.44 Million | 44.72 Million | 34.94 Million |
| Weighted Average Shares Outstanding (Diluted) | 58.72 Million | 56.44 Million | 44.72 Million | 34.94 Million |
| Gross Margin | - | 1.00 | - | 1.00 |
| EBIT Margin | - | 0.09 | - | -0.73 |
| Profit Margin | - | 0.09 | - | -0.66 |
| EBITDA | -1.82 Billion | 218.1 Million | -1.77 Billion | -687.05 Million |
| Earnings Before Tax Margin | - | 0.08 | - | -0.73 |
| Breakdown | 2024 Q4 | 2024 Q3 | 2023 FY | 2023 Q4 | 2022 FY | 2021 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | 2.5 Billion | - | - | 800 Million |
| Cost of Revenue | 989 Thousand | 995 Thousand | - | 1.53 Million | 3.14 Million | - |
| Gross Profit | -989 Thousand | -995 Thousand | 2.5 Billion | -1.53 Million | -3.14 Million | 800 Million |
| Operating Expenses | 619.58 Million | 370.17 Million | 2.28 Billion | 513.91 Million | 1.84 Billion | 1.38 Billion |
| Selling, General and Administrative Expenses | 104.24 Million | 56.82 Million | - | 65.66 Million | - | - |
| Research and Development Expenses | 515.33 Million | 313.34 Million | - | 448.24 Million | - | - |
| Other Expenses | - | - | - | - | 55.49 Million | 162.86 Million |
| Cost and Expenses | 620.57 Million | 371.16 Million | 2.28 Billion | 515.44 Million | 1.84 Billion | 1.38 Billion |
| Operating Income | -620.57 Million | -371.16 Million | 212.05 Million | -515.44 Million | -1.84 Billion | -587.66 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 605 Thousand | 605 Thousand | 2.42 Million | 605 Thousand | 2.42 Million | 1.9 Million |
| Earnings before Tax | -649.04 Million | -374.26 Million | 225.76 Million | -524.23 Million | -1.77 Billion | -525.2 Million |
| Net Income | -649.64 Million | -374.86 Million | 223.34 Million | -524.83 Million | -1.77 Billion | -527.1 Million |
| Earnings Per Share Basic | -10.25 | -6.64 | - | -9.30 | - | - |
| Earnings Per Share Diluted | -10.25 | -6.64 | - | -9.30 | - | - |
| Weighted Average Shares Outstanding | 63.38 Million | 56.45 Million | 56.44 Million | 56.44 Million | 44.72 Million | 34.94 Million |
| Weighted Average Shares Outstanding (Diluted) | 63.38 Million | 56.45 Million | 56.44 Million | 56.44 Million | 44.72 Million | 34.94 Million |
| Gross Margin | - | - | 1.00 | - | - | 1.00 |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | 0.09 | - | - | -0.66 |
| EBITDA | -648.05 Million | -370.17 Million | - | -513.91 Million | - | - |
| Earnings Before Tax Margin | - | - | 0.08 | - | - | -0.73 |
005810
MYLKF
3111
HDSN
7460
9145